For years, clinical trial technology followed a relatively straightforward model: sponsors selected the systems, and sites used them.

But our latest State of the Technology Survey suggests that model may be quietly changing.

We asked sites how often sponsors and CROs allow them to use their own technology instead of sponsor-provided systems.

The answer: about 54% of the time.

Then we asked sponsors and CROs the same question from their perspective.

Their responses were remarkably similar:

• Sponsors reported allowing site-owned technology about 46% of the time
• CROs reported about 45%

The consistency across stakeholder groups is striking.

Because it suggests this isn’t isolated experimentation anymore. It’s becoming part of the operational reality of clinical research.

And that reality is increasingly complicated.

Today, sponsors and CROs work with:

• sites with highly sophisticated technology ecosystems
• sites with partial infrastructure
• sites with almost no dedicated research technology at all

Often within the same study.

That means sponsors and CROs aren’t just managing protocols and operations anymore. They’re managing technology variability at scale.

Different site capabilities.
Different validation standards.
Different workflows.
Different support requirements.

The industry often talks about “site enablement” as though sites are a single operational category.

But the technology landscape now looks far more fragmented than that.

Some sites want sponsor-provided systems because they lack infrastructure.

Others increasingly want to use:

• their own eSource platforms
• their own eConsent tools
• their own eReg systems
• their own workflows
• their own integrations

And sponsors are slowly adapting. Not necessarily because flexibility is easy. But because enforcing complete standardization across thousands of research sites may no longer be operationally realistic.

The long-term implication is important: clinical research may be moving away from centralized technology control and toward federated operational ecosystems.

That creates opportunities:

• less duplicate data entry
• more workflow continuity at sites
• better site ownership of operations

But it also creates new complexity:

• interoperability challenges
• validation questions
• inconsistent data flows
• fragmented support models
• complexity for sponsor and CRO staff, particularly CRAs/monitors

The industry spent years trying to standardize technology deployment: from paper CRFs to EDC, from mailing sealed randomization envelopes to using IVRS, from paper questionnaires to ePRO systems. And even these technologies haven’t achieved 100% adoption across all sponsors and studies.

But this next phase of clinical trial technology is fundamentally different.

The challenge is no longer simply getting the industry to adopt a common category of technology. It’s figuring out how to operate in an ecosystem where every stakeholder may already have their own platforms, workflows, integrations, and operational preferences.

The next decade is about creating operational intelligence through systems and processes that work together and provide the study ecosystem with persistent visibility.